MedTrace Logo

GLUT-F Improves MASLD Liver Function

NCT07724067 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2026-07-23

No results posted yet for this study

Summary

This randomized, double-blind, placebo-controlled, two-period crossover study evaluated the effects of GLUT-F, a nutraceutical formulation containing silibin-enriched silymarin, glutathione, and vitamin E delivered with Enterosoma® technology, in adults with metabolic dysfunction-associated steatotic liver disease (MASLD). Participants received GLUT-F and placebo for 3 months each, separated by a 1-month washout period. The study assessed changes in hepatic steatosis, liver enzymes, metabolic parameters, inflammatory markers, and liver function measured by ultrasonography and the \^13C-methacetin breath test.

Conditions

  • MASLD (Metabolic Dysfunction-Associated Steatotic Liver Disease)

Interventions

DIETARY_SUPPLEMENT

GLUTatios FOrte

GLUT-F is an oral nutraceutical formulation containing silibin-enriched silymarin, reduced glutathione, and vitamin E encapsulated using Enterosoma® technology to enhance intestinal absorption and bioavailability. Participants received one sachet daily for 3 months. The placebo was identical in appearance, taste, and packaging but contained no active ingredients.

DIETARY_SUPPLEMENT

Placebo

The placebo consisted of an oral formulation identical to GLUT-F in appearance, taste, packaging, and mode of administration, but containing no active ingredients. It was administered as one sachet daily for 3 months to maintain participant and investigator blinding.

Sponsors & Collaborators

  • University of Bari

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-01
Primary Completion
2025-09-10
Completion
2026-05-15

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07724067 on ClinicalTrials.gov